Newsbenzinga
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…